| Literature DB >> 12407134 |
Cressida Auckland1, Louise Teare, Fiona Cooke, Mary E Kaufmann, Marina Warner, Graeme Jones, Kathy Bamford, Helen Ayles, Alan P Johnson.
Abstract
Linezolid, the first oxazolidinone antibacterial agent to be developed for clinical use, was licensed in the UK in early 2001. We report the first three examples of resistant enterococci (two isolates of Enterococcus faecium and one Enterococcus faecalis) isolated in the UK, which were obtained from patients who had received linezolid. The linezolid MICs for the resistant isolates were 64 mg/L. Pulsed-field gel electrophoresis (PFGE) analysis of the linezolid-susceptible and -resistant isolates from two of the patients, combined with sequence analysis of rRNA, indicated that resistance developed in previously susceptible strains, most probably via a point mutation in the 23S rRNA.Entities:
Mesh：
Substances：
Year: 2002 PMID： 12407134 DOI： 10.1093/jac/dkf246
Source DB: PubMed Journal: J Antimicrob Chemother ISSN： 0305-7453 Impact factor: 5.790